Brand Institute, announced its successful partnership with Arvinas, Inc. on the development of the nonproprietary name bavdegalutamide. Bavdegalutamide, also referred to as ARV-110, was published as a recommended INN in April of 2022. The product was granted fast-track designation by the FDA in May of 2019 for the treatment of metastatic castration-resistant prostate cancer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
35.23 USD | 0.00% | +7.80% | -14.41% |
05-23 | Arvinas, Inc. Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress | CI |
05-16 | Sector Update: Health Care Stocks Steady Premarket Thursday | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.41% | 2.41B | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- ARVN Stock
- News Arvinas, Inc.
- Brand Institute Partners on Nonproprietary Name for Novel Protein Degrader Under Development by Arvinas, Inc